Passage Bio Inc

-0.05 (-0.29%)
Other Pre-Announcement

Passage Bio Publishes Data That Show Single Injection Of Optimized AAV Vector Into CSF Corrects Neurological Disease

Published: 10/13/2020 21:23 GMT
(PASG) - Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized Aav Vector Into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of Pbgm01 Into Clinic.
Passage Bio Inc - Expects to Initiate Dosing of Pbgm01 in a Phase 1/2 Trial Late in Q4 of 2020 Or Early in Q1 of 2021.
Passage Bio Inc - Remains on Track to Report Initial 30-day Safety and Biomarker Data Late in First Half of 2021.